Generate Biomedicines, Inc. (GENB)

Generate Biomedicines will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

Generate Biomedicines Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Net Income	-203.15	-173.77
Depreciation & Amortization	10.4	9.9
Share-Based Compensation	20.58	19.47
Other Operating Activities	-8.63	34.27
Operating Cash Flow	-200.62	-117.75
Capital Expenditures	-3.51	-3.45
Change in Investments	120.28	-54.29
Other Investing Activities	-	0.01
Investing Cash Flow	116.77	-57.73
Share Issuance / Repurchase	23.07	97.45
Debt Issued / Paid	-8.16	-11.12
Other Financing Activities	13.15	5
Financing Cash Flow	28.06	91.33
Net Cash Flow	-55.79	-84.15
Free Cash Flow	-204.13	-121.2
Free Cash Flow Margin	-640.06%	-592.39%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).